Sarepta Faces Share Drop Amid Elevidys Safety Concerns

Introduction

Sarepta Therapeutics Inc. (NASDAQ: SRPT) is a biotechnology company based in Cambridge, Massachusetts, focused on precision genetic medicine for rare neuromuscular diseases. As of June 16, 2025, the stock traded at $18.94, down 47.65% on the day, with a trading volume of 14.2 million shares. The 52-week trading range spans $18.30 to $173.25.

Corporate Structure

Founded in 2012, Sarepta employs between 1,001 and 5,000 people worldwide. The company’s multi-platform Precision Genetic Medicine Engine supports more than 40 programs in various stages of development. Its portfolio encompasses gene therapy, RNA-based therapies, and gene editing. It currently markets one gene therapy and three RNA-based drugs in the United States.

Developments and News

On June 9, 2025, Sarepta’s share price decreased 41% in premarket trading following the company’s report of a second death from acute liver failure related to its Duchenne muscular dystrophy gene therapy, Elevidys. In response, Sarepta announced plans to update the Elevidys label to strengthen safety warnings for non-ambulatory individuals.

On May 15, 2025, the U.S. Food and Drug Administration (FDA) granted Platform Technology Designation to the adeno-associated viral vector used in SRP-9003, Sarepta’s investigational gene therapy for limb-girdle muscular dystrophy type 2E/R4. In May, the company presented one-year follow-up data from its ENVISION study, showing mobility improvements in 8- to 9-year-old Duchenne patients treated with Elevidys.

Earlier in June, Sarepta filed an 8-K with the SEC (Filing Date: June 6, 2025), indicating changes in executive leadership, matters submitted to a shareholder vote, and updated financial statements and exhibits. The quarterly 10-Q was filed on May 6, 2025, and the Annual Report to Security Holders appeared on April 24, 2025.

Financial and Strategic Analysis

For the trailing twelve months through March 31, 2025, Sarepta reported revenue of $2.23 billion and a net loss of $248.4 million, reflecting an 11.1% negative profit margin. The company held $522.8 million in cash against a total debt/equity ratio of 118.7%. Operating leverage remains under pressure, as evidenced by a levered free cash flow deficit of $741.3 million.

On the balance sheet, total enterprise value stood at $4.38 billion against a market capitalization of $3.56 billion. The stock carries a beta of 0.60. There is currently no dividend available, and the forward price-to-earnings ratio is 23.6x based on consensus earnings projections for FY 2026.

Strategically, Sarepta continues to invest in research and development across neuromuscular, central nervous system, and cardiology indications. The pipeline offers multiple upcoming regulatory catalysts, including potential biologics license applications for limb-girdle muscular dystrophy (LGMD) and expanded Duchenne filings.

Market Position and Industry Context

Within the Duchenne muscular dystrophy segment, Sarepta holds a leadership position alongside competitors such as Wave Life Sciences, Dyne Therapeutics, and Avidity Biosciences, all focused on next-generation treatments. The FDA’s Platform Technology Designation for SRP-9003 highlights regulatory recognition of the company’s vector platform.

Biotechnology equities have faced heightened volatility in 2025, driven by safety concerns in gene therapies, supply chain constraints, and macroeconomic conditions. Sarepta’s share decline from its February 2025 peak reflects both the Elevidys safety issue and broader risk sentiment toward high-beta innovation stocks.

TL;DR

On June 9, 2025, Sarepta’s shares fell following a second post-treatment liver failure death associated with Elevidys, prompting a label update. On May 15, 2025, the FDA granted Platform Technology Designation for the SRP-9003 viral vector. The company reported $2.23 billion in revenue and a $248 million net loss for the trailing year, with $522.8 million in cash and a debt/equity ratio of 118.7%. Upcoming clinical and regulatory milestones for LGMD and Duchenne programs will influence Sarepta’s outlook through 2026.